• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Consumer Cyclical·CLV.AX
Share

Clover Corporation Limited Stocks

A$ 0.89Last Updated 11.09.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

A$ 114.30M

A$ 0.89
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Clover Corporation Limited engages in the processing and worldwide sale of natural oils, reaching markets across Australia, New Zealand, Asia, Europe, and the Americas. The company's operations also encompass the creation of encapsulated products and extensive research and development focused on functional food and infant nutrition ingredients. Among its principal offerings are Nu-Mega Hi docosahexaenoic tuna oils, designed for use in infant formula and pharmaceutical goods, alongside its Ocean Gold refined tuna oils. Furthermore, it supplies Nu-Mega Driphorm powders, which are incorporated into various infant formulas, follow-on formulas, growing-up milks, and general food products, as well as Nu-Mega Driphorm HA for non-dairy applications. These products cater to several segments, including active living (for immune and sports support), healthy living (benefiting brain and heart health), and the foundational stages of infant and child development. The company, founded in 1988, maintains its corporate headquarters in Altona North, Australia.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of CLV.AX is 0.87 and suggests 6.45% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.09.2026 18:37

U.S. stocks jumped more than 1% following the release of inflation data

11.09.2026 17:37

Inflation in the U.S. in August came in slightly above expectations. What can we expect from the Fed now?

11.09.2026 17:24

"A Recipe for Volatility": Why BofA Sees Risks in Market Calm

11.09.2026 15:00

Uber's CEO Invested $10 Million in the Company's Shares, Which Had Fallen in Price

11.09.2026 13:30

An investor from "Shorting" advised buying wine amid the dollar's decline

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026